Europe Automated Intravenous Oncology Compounding Devices Market Size By Product Type, By Technology, By End-Use, By Geographic Scope And Forecast

Europe Automated Intravenous Oncology Compounding Devices Market Size And Forecast

Europe Automated Intravenous Oncology Compounding Devices Market size was valued at USD 761.3 Million in 2024 and is projected to reach USD 1,246.6 Million by 2032 growing at a CAGR of 7.10% from 2026 to 2032.

A fully automated compounding system mixes one or more medication solutions into a final container for patient administration. The Automated Intravenous Oncology Compounding Devices Market is increasing in Europe, owing to increased acceptance of chemotherapy and customized medication, as well as a growing demand to reduce drug errors. The Europe Automated Intravenous Oncology Compounding Devices Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Europe Automated Intravenous Oncology Compounding Devices Market Definition

Automated Compounding Devices (Oncology) are devices that assist in the aseptic transfer of one or more sterile component solutions to a sterile final container for patient preparation, reducing the need for syringes. The devices are known for providing superior ingredient distribution precision, as well as lowering preparation time and limiting patient injuries. This helps prevent prescription mistakes caused by a range of variables including inadequate management communication between the physician and pharmacist, important pharmacy storage procedures, and confusion caused by the usage of identical labels.

Automated compounding technologies, on the other hand, have enhanced the precision and efficiency of administering compounded pharmaceuticals while also reducing the exposure of healthcare practitioners to harmful substances. The gravimetric method and the volumetric methods are the two basic approaches employed in ACD technology. Furthermore, the chemotherapeutic medicines involved are sometimes very toxic, with a poor therapeutic index, necessitating the use of high-precision drug preparation.

The precision of these ACDs is related to the volume that must be transmitted, implying that the bigger the volume, the higher the device's accuracy. As a result, manufacturers provide a variety of transferable volumes to meet the demands of a wide spectrum of clients. The gadgets are used to measure powdered and liquid components in both hospitals and pharmacies.

Europe Automated Intravenous Oncology Compounding Devices Market Overview

Europe Automated Intravenous Oncology Compounding Devices Market is expected to increase due to the rising adoption of chemotherapy and customized medicine, better efficiency & accuracy of the device, reduced exposure to cytotoxic material, and a reduced risk of contamination. Furthermore, the market is driven by the decrease in hospital per-dose costs and the removal of contamination that is necessary when compounding solutions.

The increased need to reduce medical mistakes is also a driving force for the growth. Additionally, during the projected period, the adoption of new robotic technology automation in compounding systems is expected to boost the market growth. However, the high installation cost of devices, reluctance to accept devices, and lacked skilled resources are major restraints to the market's growth.

Europe Automated Intravenous Oncology Compounding Devices Market: Segmentation Analysis

The Europe Automated Intravenous Oncology Compounding Devices Market is Segmented on the basis of Product Type, Technology, End-Use, And Geography.

Europe Automated Intravenous Oncology Compounding Devices Market, By Product Type

• Macro Devices
• Micro Devices
• Major/Micro Devices

Based on Product Type, The market is segmented into Macro Devices, Micro Devices, Major/Micro Devices. Macro devices are used in hospitals for radiation purposes, thus they are projected to dominate the market.

Europe Automated Intravenous Oncology Compounding Devices Market, By Technology

• Gravimetric Devices
• Volumetric Devices

Based on Technology, The market is segmented into Gravimetric Devices and Volumetric Devices. In the treatment of cancer, gravimetric analysis employs quartz crystal microbalance (QCM) transducers and synthetic receptors, which is predicted to boost the market.

Europe Automated Intravenous Oncology Compounding Devices Market, By End-Use

• Hospitals
• Chemotherapy Centers

Based on End-Use, The market is segmented into Hospitals and Chemotherapy Centers. Hospitals are expected to rise the most during the forecasted period due to an increased number of patients with Cancer, reduced medication errors, and cost-effectiveness.

Europe Automated Intravenous Oncology Compounding Devices Market, By Geography

• Germany
• U.K.
• France
• Rest of Europe
• On the basis of Geography, The Europe Automated Intravenous Oncology Compounding Devices Market is classified into Germany, U.K., France, and the Rest of Europe.

Key Players

• The " Europe Automated Intravenous Oncology Compounding Devices Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Comecer, Locioni, ICU Medical, Baxter Healthcare Corporation, SA Equashield, B. Braun Medical Inc., Omnicell Inc, Arxium, Grifols International, and Weibond Technologies.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In 2019, Fagron & JCB Laboratories opened one of the largest 503B human drug outsourcing facilities.
• In December 2018, Arxium introduced its cGMP RIVA IV, a fully automated compounding system for hospitals.